Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 14, 2014; 20(30): 10223-10237
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10223
Current management of hepatocellular carcinoma
Parissa Tabrizian, Sasan Roayaie, Myron E Schwartz
Parissa Tabrizian, Sasan Roayaie, Myron E Schwartz, Mount Sinai Liver Cancer Program, Mount Sinai Medical Center, New York, NY 10029, United States
Author contributions: Tabrizian P, Roayaie S and Schwartz ME contributed equally to the conception and design of data; Tabrizian P and Schwartz ME acquisition of data, drafting, and final approval of the article.
Correspondence to: Myron E Schwartz, MD, FACS, Mount Sinai Liver Cancer Program, Mount Sinai Medical Center, 1 Gustave Levy Place, Box 1104, New York, NY 10029, United States. myron.schwartz@mountsinai.org
Telephone: +1-212-6598084 Fax: +1-212-2412138
Received: January 9, 2014
Revised: May 8, 2014
Accepted: May 25, 2014
Published online: August 14, 2014
Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and leading cause of death among patients with cirrhosis. Treatment guidelines are based according to the Barcelona Clinic Liver Cancer staging system. The choice among therapeutic options that include liver resection, liver transplantation, locoregional, and systemic treatments must be individualized for each patient. The aim of this paper is to review the outcomes that can be achieved in the treatment of HCC with the heterogeneous therapeutic options currently available in clinical practice.

Keywords: Hepatocellular carcinoma, Management, Barcelona Clinic Liver Cancer guidelines, Therapeutic options, Outcome

Core tip: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and its incidence is rising in Western countries. The choice among therapeutic options that include liver resection, liver transplantation, locoregional, and systemic treatments must be individualized for each patient. The aim of this paper is to review the outcomes that can be achieved in the treatment of HCC with the heterogeneous therapeutic options currently available in clinical practice.